Your browser doesn't support javascript.
loading
Rare loss-of-function variants in SETD1A are associated with schizophrenia and developmental disorders.
Singh, Tarjinder; Kurki, Mitja I; Curtis, David; Purcell, Shaun M; Crooks, Lucy; McRae, Jeremy; Suvisaari, Jaana; Chheda, Himanshu; Blackwood, Douglas; Breen, Gerome; Pietiläinen, Olli; Gerety, Sebastian S; Ayub, Muhammad; Blyth, Moira; Cole, Trevor; Collier, David; Coomber, Eve L; Craddock, Nick; Daly, Mark J; Danesh, John; DiForti, Marta; Foster, Alison; Freimer, Nelson B; Geschwind, Daniel; Johnstone, Mandy; Joss, Shelagh; Kirov, Georg; Körkkö, Jarmo; Kuismin, Outi; Holmans, Peter; Hultman, Christina M; Iyegbe, Conrad; Lönnqvist, Jouko; Männikkö, Minna; McCarroll, Steve A; McGuffin, Peter; McIntosh, Andrew M; McQuillin, Andrew; Moilanen, Jukka S; Moore, Carmel; Murray, Robin M; Newbury-Ecob, Ruth; Ouwehand, Willem; Paunio, Tiina; Prigmore, Elena; Rees, Elliott; Roberts, David; Sambrook, Jennifer; Sklar, Pamela; St Clair, David.
Afiliação
  • Singh T; Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK.
  • Kurki MI; Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
  • Curtis D; Program in Medical and Population Genetics and Genetic Analysis Platform, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  • Purcell SM; University College London Genetics Institute, University College London, London, UK.
  • Crooks L; Division of Psychiatric Genomics, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • McRae J; Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK.
  • Suvisaari J; Sheffield Diagnostic Genetics Service, Sheffield Childrens' NHS Foundation Trust, Sheffield, UK.
  • Chheda H; Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK.
  • Blackwood D; National Institute for Health and Welfare (THL), Helsinki, Finland.
  • Breen G; Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
  • Pietiläinen O; Division of Psychiatry, The University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK.
  • Gerety SS; Institute of Psychiatry, Kings College London, London, UK.
  • Ayub M; NIHR BRC for Mental Health, Institute of Psychiatry and SLaM NHS Trust, King's College London, London, UK.
  • Blyth M; Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK.
  • Cole T; Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
  • Collier D; National Institute for Health and Welfare (THL), Helsinki, Finland.
  • Coomber EL; Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK.
  • Craddock N; Division of Developmental Disabilities, Department of Psychiatry, Queen's University, Kingston, Ontario, Canada.
  • Daly MJ; Department of Clinical Genetics, Chapel Allerton Hospital, Chapeltown Road, Leeds, UK.
  • Danesh J; Birmingham Women's Hospital, Edgbaston, Birmingham, UK.
  • DiForti M; Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's College London, London, UK.
  • Foster A; Lilly Research Laboratories, Eli Lilly &Co. Ltd., Windlesham, Surrey, UK.
  • Freimer NB; Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK.
  • Geschwind D; MRC Centre for Neuropsychiatric Genetics &Genomics, Institute of Psychological Medicine &Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, UK.
  • Johnstone M; Program in Medical and Population Genetics and Genetic Analysis Platform, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  • Joss S; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  • Kirov G; Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK.
  • Körkkö J; NIHR Blood and Transplant Research Unit in Donor Health and Genomics, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Kuismin O; INTERVAL Coordinating Centre, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Holmans P; Institute of Psychiatry, Kings College London, London, UK.
  • Hultman CM; Clinical Genetics Unit, Birmingham Women's NHS Foundation Trust, Edgbaston, Birmingham, UK.
  • Iyegbe C; Center for Neurobehavioral Genetics, University of California Los Angeles, Los Angeles, California, USA.
  • Lönnqvist J; UCLA David Geffen School of Medicine, Los Angeles, California, USA.
  • Männikkö M; Division of Psychiatry, The University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK.
  • McCarroll SA; West of Scotland Genetics Service, South Glasgow University Hospitals, Glasgow, UK.
  • McGuffin P; MRC Centre for Neuropsychiatric Genetics &Genomics, Institute of Psychological Medicine &Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, UK.
  • McIntosh AM; Center for Intellectual Disability Care, Oulu University Hospital and University of Oulu, Oulu, Finland.
  • McQuillin A; PEDEGO Research Unit, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.
  • Moilanen JS; MRC Centre for Neuropsychiatric Genetics &Genomics, Institute of Psychological Medicine &Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, UK.
  • Moore C; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Murray RM; Institute of Psychiatry, Kings College London, London, UK.
  • Newbury-Ecob R; National Institute for Health and Welfare (THL), Helsinki, Finland.
  • Ouwehand W; Center for Life Course Epidemiology and Systems Medicine, University of Oulu, Oulu, Finland.
  • Paunio T; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  • Prigmore E; Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA.
  • Rees E; Institute of Psychiatry, Kings College London, London, UK.
  • Roberts D; Division of Psychiatry, The University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK.
  • Sambrook J; University College London, Molecular Psychiatry Laboratory, Division of Psychiatry, London, UK.
  • Sklar P; PEDEGO Research Unit, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.
  • St Clair D; NIHR Blood and Transplant Research Unit in Donor Health and Genomics, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Nat Neurosci ; 19(4): 571-7, 2016 Apr.
Article em En | MEDLINE | ID: mdl-26974950
ABSTRACT
By analyzing the whole-exome sequences of 4,264 schizophrenia cases, 9,343 controls and 1,077 trios, we identified a genome-wide significant association between rare loss-of-function (LoF) variants in SETD1A and risk for schizophrenia (P = 3.3 × 10(-9)). We found only two heterozygous LoF variants in 45,376 exomes from individuals without a neuropsychiatric diagnosis, indicating that SETD1A is substantially depleted of LoF variants in the general population. Seven of the ten individuals with schizophrenia carrying SETD1A LoF variants also had learning difficulties. We further identified four SETD1A LoF carriers among 4,281 children with severe developmental disorders and two more carriers in an independent sample of 5,720 Finnish exomes, both with notable neuropsychiatric phenotypes. Together, our observations indicate that LoF variants in SETD1A cause a range of neurodevelopmental disorders, including schizophrenia. Combining these data with previous common variant evidence, we suggest that epigenetic dysregulation, specifically in the histone H3K4 methylation pathway, is an important mechanism in the pathogenesis of schizophrenia.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esquizofrenia / Variação Genética / Histona-Lisina N-Metiltransferase / Estudos de Associação Genética / Transtornos do Neurodesenvolvimento Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male País/Região como assunto: Europa Idioma: En Revista: Nat Neurosci Assunto da revista: NEUROLOGIA Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esquizofrenia / Variação Genética / Histona-Lisina N-Metiltransferase / Estudos de Associação Genética / Transtornos do Neurodesenvolvimento Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male País/Região como assunto: Europa Idioma: En Revista: Nat Neurosci Assunto da revista: NEUROLOGIA Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Reino Unido